<DOC>
	<DOC>NCT00939562</DOC>
	<brief_summary>The purpose of this protocol is to study if two different tablet formulations of doxycycline are bioequivalent to each other.</brief_summary>
	<brief_title>Bioequivalence Between Two Tablet Formulations Of Doxycycline Carragenate</brief_title>
	<detailed_description />
	<mesh_term>Bacterial Infections</mesh_term>
	<mesh_term>Doxycycline</mesh_term>
	<criteria>Healthy male subjects between the ages of 18 and 55 years. Body Mass Index (BMI) of 18 to 30 kg/m2. Evidence or history of clinically significant abnormality. Any condition possibly affecting drug absorption. A positive urine drug screen.</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>Bioequivalence</keyword>
</DOC>